Format

Send to

Choose Destination
Blood. 2019 Apr 16. pii: blood.2019000478. doi: 10.1182/blood.2019000478. [Epub ahead of print]

Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution.

Author information

1
National Institutes of Health, United States.
2
National Heart, Lung, and Blood Institute, United States.
3
Genentech, United States.
4
Tallaght University Hospital, Ireland.
5
National Heart, Lung and Blood Institute, United States.
6
Oncology, Clinical Development, AstraZeneca MedImmune, United States.
7
Division of Hematology, Hospital A BeneficĂȘncia Portuguesa, Brazil.
8
Cellular and Molecular Therapeutics Branch, National Institutes of Health, United States.
9
NHLBI, United States.
10
Nhlbi, NIH, United States.
11
Hematology, National Institutes of Health, United States.
12
Office of Biostatistics Research, National Heart, Lung and Blood Institute, NIH, United States.
13
NIH, United States.
14
Center for Cancer Research, Department of Laboratory Medicine, National Institutes of Health, United States.
15
NHLBI, NIH, United States.
16
Translational Stem Cell Biology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, United States dunbarc@nhlbi.nih.gov.

Abstract

Eltrombopag received FDA approval for the treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with doses escalating from 50-150mg daily for 12 weeks. Response kinetics suggested that more prolonged administration of EPAG at a dose of 150 mg could speed and improve response rates. We enrolled 40 rSAA patients in a study of EPAG 150mg daily, with a primary endpoint of response at 24 weeks. Twenty of 40(50%) responded at 24 weeks, 5/20(25%) would have been deemed non-responders at 12 weeks, the endpoint of the prior study. 15/19 responding patients continuing on EPAG had drug discontinued for robust response with 5/15 requiring EPAG re-initiation for relapse in 5/15, with all recovering response. To analyze risk of clonal progression, we combined long-term data from the 83 rSAA patients enrolled in both studies. Evolution to an abnormal karyotype occurred in 16(19%), most within 6 months of EPAG initiation. Targeted deep sequencing/whole exome sequencing was performed pre-EPAG and at primary response endpoint, and/or time of clonal evolution or longest follow-up. Cytogenetic evolution did not correlate with mutational status, and overall mutated allele fractions of myeloid cancer genes did not increase on EPAG. In summary, extended administration of EPAG at a dose of 150mg for 24 weeks rescued responses in some patients with rSAA not responding at 12 weeks. The temporal relationship between clonal evolution and drug exposure suggests that EPAG may promote expansion of dormant pre-existing clones with an aberrant karyotype. The studies are registered at www.clinicaltrials.gov as NCT00922883 and NCT01891994.

PMID:
30992268
DOI:
10.1182/blood.2019000478

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center